The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient

• Status: Not yet recruiting
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Male

Summary

The objective of this study is to evaluate the predictive value of TMPRSS2-ERG gene fusion in patients with prostate cancer treated with radiation and hormonal therapy.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
• Treatments: Triptorelin Pamoate

Criteria

Inclusion Criteria: One of the following

• T3a +

• PSA > 20

• Gleason 8 or higher

• Karnofsky performance status ≥ 70.

• Signed study-specific informed consent